Skip to menu

Min-Soo Kim's blog

Experience

Education

Publications

  1. M-S Kim, DM Hajducek, JC Gilbert, A Iorio, B Jilma, AN Edginton. Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans. AAPS Journal. 2024; DOI: 10.1208/s12248-024-00952-4 
  2. H Kwak, M-S Kim, S Kim, J Kim, Y Aoki, S-J Chung, H-J Nam, W Lee. Kinetic modeling of the plasma pharmacokinetic profiles of ADAMTS13 fragment and its Fc-fusion counterpart in mice. Frontiers in Pharmacology. 2024; DOI: 10.3389/fphar.2024.1352842
  3. M-S Kim, Y-K Song, J-S Choi, HY Ji, E Yang, JS Park, HS Kim, M-J, Kim, I-K, Cho, S-J, Chung, Y-J Chae, K-R Lee. Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans. Pharmaceutics. 2023; DOI: 10.3390/pharmaceutics15030942
  4. W Lee, M-S Kim, J Kim, Y Aoki, Y Sugiyama. Predicting in vivo Target Occupancy (TO) Profiles via PBPK-TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions. Drug Metabolism and Disposition. 2023; DOI: 10.1124/dmd.122.000968
  5. J-H Nam, M-S Kim, Y-J Song, C-H Kim, WS Kim, CH Yu, HE Joe, GH Hur, M-R Seo, Y Kim, KE Park, JY Choi, S-J Chung, YK Shin. Pretreatment of rhesus monkeys with transdermal patches containing physostigmine and procyclidine: implications of the delivery system for the potential application against VX nerve agent intoxication in humans. Archives of Toxicology. 2023; DOI: 10.1007/s00204-022-03438-4.
  6. S Lee, M-S Kim, J-W Jeong, J Chae, T-S Koo, H-J Maeng, S-J Chung, K-R Lee, Y-J Chae. Bioanalysis of alpelisib using liquid chromatography–tandem mass spectrometry and application to pharmacokinetic study. Journal of Analytical Science and Technology. 2022; DOI: 10.1186/s40543-022-00340-7.
  7. Y-S Jeong, M-S Kim, S-J Chung, Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically-Based Pharmacokinetic (PBPK) Models I: Theoretical Consideration of Bottom-up Approach of Lumping Tissues in Whole-Body PBPK. AAPS Journal. 2022.
  8. Y-S Jeong, M-S Kim, S-J Chung, Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically-Based Pharmacokinetic (PBPK) Models II: Practical Application of Tissue Lumping Theories for Pharmacokinetics of Various Compounds. AAPS Journal. 2022.
  9. Y-K Song, M-J Kim, M-S Kim, J Lee, S-J Chung, J Song, Y-J Chae, K-R Lee, Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice. European Journal of Pharmaceutical Sciences. 2022; 173.
  10. M-S Kim, N Lee, A Lee, Y-J Chae, S-J Chung, and K-R Lee. Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans. Pharmaceuticals. 2022; 15(6):709.
  11. M Lee, Y-S Jeong, M-S Kim, K-M An, and S-J Chung. Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics. Pharmaceutics. 2022; 14(6):1157.
  12. Y-S Jeong, M-S Kim, N Lee, Y-J Chae, S-J Chung, and K-R Lee. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. Pharmaceutics. 2021;13(6):813.
  13. Y-J Chae, M-S Kim, S-J Chung, M-K Lee, K-R Lee, and H-J Maeng. Pharmacokinetic Estimation Models-based Approach to Predict Clinical Implications for CYP Induction by Calcitriol in Human Cryopreserved Hepatocytes and HepaRG Cells. Pharmaceutics. 2021;13(2):181.
  14. Y-S Jeong, M Baek, S Lee, M-S Kim, H-J Maeng, J-H Lee, Y-G Suh, and S-J Chung. Development and Validation of Analytical Method for SH-1242 in the Rat and Mouse Plasma by Liquid Chromatography/Tandem Mass Spectrometry. Molecules. 2020;25(3):531.
  15. Y-K Song, JE Park, Y Oh, S Hyung, Y-S Jeong, M-S Kim, W Lee, and S-J Chung. Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib. Journal of Pharmacology and Experimental Therapeutics. 2019;368(1):79.
  16. J-H Son, Y-S Jeong, J-H Lee, M-S Kim, K-R Lee, C-K Shim, Y-H Kim, and S-J Chung. Identification of metabolites of MDR-1339, an inhibitor of β-amyloid protein aggregation, and kinetic characterization of the major metabolites in rats. Journal of Pharmaceutical and Biomedical Analysis. 2018;151:61-70.
  17. S Hyung, Y-S Jeong, J Yeo, Y-K Song, M-S Kim, Y-J Im, H-J Maeng, and S-J Chung. Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. European Journal of Pharmaceutical Sciences. 2018;123:312-20.
  18. Y Oh, Y-S Jeong, M-S Kim, JS Min, G Ryoo, JE Park, Y Jun, Y-K Song, S-E Chun, S Han, SK Bae, S-J Chung, and W Lee. Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media. Journal of Pharmaceutical Sciences. 2018;107(6):1713-23.
  19. C-K Noh, J-H Lee, M-S Kim, H-J Maeng, and S-J Chung. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC–MS/MS for application to a pharmacokinetic study in rats. Journal of Separation Science. 2017;40(19):3782-91.

Presentation

  1. M-S Kim, Development of mechanistic PK/PD model for BT200, a new drug candidate for hemophilia, St. Jude PK/PD Webinar (St. Jude Children's Research Hospital, Memphis, Tennessee, USA), Dec. 2023 (Oral presentation).
  2. Y-S Jeong, M-S Kim, N Lee, A Lee, Y-J Chae, S-J Chung, and K-R Lee. Physiologically based pharmacokinetic - pharmacodynamic modeling for the estimation of effective dosing regimen for orally administered fexuprazan in humans, 2022 Annual Meeting and International Conference of the Korean Society of Pharmaceutical Sciences and Technology, Seoul, Republic of Korea (Dec. 2022; Oral presentation).
  3. C-S Yim, M-S Kim, Y-S Jeong, S-Y Lee, H-M Ryu, W Lee, D-D Kim, S-J Chung, Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport, 2018 International Conference on the Korean Society of Pharmaceutical Sciences and Technology, Busan, Republic of Korea (Nov. 2018; Poster).
  4. C-S Yim, M-S Kim, Y-S Jeong, S-Y Lee, H-M Ryu, W Lee, D-D Kim, S-J Chung, rOatp1b2-Mediated Interaction in the Hepatic Uptake of Lobeglitazone by Atorvastatin, 2018 International Meeting on 22nd MDO and 33rd JSSX in Kanazawa, Japan (Oct. 2018; Poster).

Workshop participation

  • 2018, 2019, and 2022: 1st-3rd Korean Pharmacokinetics Bootcamp Workshop at Seoul National University, Seoul, Republic of Korea (1-day workshop)
    • This workshops were mainly organized by Professor Suk-Jae Chung and Wooin Lee
    • The workshop consisted of lectures and hands-on problem sets for the industrial researchers
    • I was involved in developing the problem sets
  • 2017: Simcyp Workshop “Model-informed drug development: Incorporating population variability into mechanistic prediction of PK and modeling” Busan, Republic of Korea (5-day workshop).

Honors and Awards

Skills

  • Pharmacokinetic modeling using Berkeley Madonna, WinNonlin, Python, R, MATLAB, NONMEM, Simcyp, and PK-Sim
  • Non-compartmental and compartment model-based analysis
  • Quantitative analysis using HPLC-UV and HPLC-MS/MS
  • Protein bindings: Plasma protein binding assay using rapid equilibrium dialysis kit; Blood-to-plasma partition coefficient assay using depletion method
  • Animal experiments: Femoral vein and artery cannulation in rats; Jugular vein cannulation in rats; Tissue distribution study after intravenous infusion in rats; Pharmacokinetic analysis after intravenous bolus and oral administration in rats and mice
  • Nucleotide quantitation: qPCR; Nano-drop
  • Cell works: Subculture; Uptake assay; Bi-directional permeability assay; Cell counting; Viability assay using trypan blue exclusion assay

Research Interests

  • Pharmacokinetics
  • Physiologically-based pharmacokinetic modeling
  • Pharmacokinetic modeling

License

  • Registered pharmacist, Republic of Korea

Links